Added to YB: 2024-09-02
Pitch date: 2024-08-30
SPRY [bullish]
ARS Pharmaceuticals, Inc.
-26.31%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
Market Cap
$927.2M
Pitch Price
$12.81
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.05
P/E
-11.50
EV/Sales
5.66
Sector
Biotechnology
Category
growth
Show full summary:
Are the best drugs injected or snorted? No, not those kinds of drugs!: ARS Pharmaceuticals $SPRY
SPRY: FDA-approved nasal epinephrine spray Neffy targets $1B EpiPen market. Patent until 2038, $200M cash for commercialization. Potential 3-10x return based on market penetration. Risks: marketing execution, high short interest. CEO/CMO couple own 10%. Narcan-experienced CCO. Small position recommended for non-experts.
Read full article (6 min)